Compare Mesoblast Limited (MESO) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Standard Lithium Ltd — how do they compare? Mesoblast Limited trades at $14.33 (market cap $1.75B), while Standard Lithium Ltd trades at $1.62 (market cap $398.07M). The key difference: Mesoblast Limited is far larger — about 4.4× Standard Lithium Ltd's market cap, and Mesoblast Limited is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Standard Lithium Ltd for 23 Days on average.
| MESO | SLI | |
|---|---|---|
Market Cap | $1.75B | $398.07M |
Volume | 239,027 | 1,564,155 |
Sector | Health | Basic Materials |
52-Week High | $20.96 | $5.65 |
52-Week Low | $13.19 | $1.61 |
Typical Hold Time | 14 Days | 23 Days |
Enterprise Value | $1.83B | $260.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Standard Lithium (SLI) trades at $1.65, down 4.62% today, with a bearish technical signal despite bullish oscillators. The company shows negative profitability with ROE of -15.55% and ROA of -14.17%, though recent quarterly EPS beat expectations. Positive developments include progress toward a 2026 final investment decision for the Arkansas lithium project and expanded offtake agreements. Cash flow remains supported by financing activities despite negative operational cash flow.
The investment case hinges on successful project execution and lithium market dynamics. Analysts are unanimously bullish with a $3.83 price target, representing significant upside. Key risks include execution delays, negative cash flow, and commodity price volatility. The stock offers high-risk, high-reward exposure to North American lithium production growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
